Meta-analysis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease

Yukari Masunaga, Keiko Ohno, Ryuichi Ogawa, Masayuki Hashiguchi, Hirotoshi Echizen, Hiroyasu Ogata

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

BACKGROUND: There is a concern as to whether long-term administration of immunosuppresants in patients with inflammatory bowel disease (IBD) would increase the risk of malignancy. OBJECTIVE: To compare the risks of developing malignancy between patients with IBD treated with immonosuppressive agents and patients with IBD not receiving these agents. METHODS: A systematic literature review was conducted, and a meta-analysis was performed on data retrieved from cohort studies that followed patients with IBD who received immunosuppressive agents for more than a year and documented the incidence of newly developed malignancy. An electronic search was conducted using MEDLINE (1966-September 2006), the Cochrane Library (issue 3, 2006), and Japana Centra Revou Medicina (1981-September 2006). Medical subject headings used in the searches were azathioprine, 6-mercaptorine, cyclosporine, methotrexate, tacrolimus, inflammatory bowel disease, and neoplasms. We imposed no language limitation in the searches. Additionally, a manual search of reference listings from all articles retrieved from the electronic databases was performed. Using data obtained from control groups or population-based studies, the incidence of newly developed malignancy in patients with IBD treated with immunosuppressive agents was compared with that of patients with IBD who were not receiving immunosuppressive agents. Statistical analysis for the change in risk of receiving immunosuppressive agents. Statistical analysis for the difference (WMD) normalized to per person-year and its 95% confidence interval. RESULTS: Nine cohort studies met the inclusion criteria for this meta-analysis. Analysis of these studies showed no discernible difference (WMD -0.3 × 10 -3/ person-year; 95% CI -1.2 × 10-3) in the incidence of any kind of malignancy in patients with IBD who received immunosuppressants compared with those who did not receive immunosuppresants. No significant difference in WMD was observed when the data from patients with either Crohn's disease (CD) or ulcerative colitis (UC) were analyzed separately. CONCLUSIONS: Our findings suggest that the administration of immunosuppressive agents in patients with either CD or UC probably does not confer a significantly increased risk of malignancy compared with patients with IBD who are not receiving these agents.

Original languageEnglish
Pages (from-to)21-28
Number of pages8
JournalAnnals of Pharmacotherapy
Volume41
Issue number1
DOIs
Publication statusPublished - 2007 Jan
Externally publishedYes

Fingerprint

Immunosuppressive Agents
Inflammatory Bowel Diseases
Meta-Analysis
Pharmaceutical Preparations
Neoplasms
Cohort Studies
Ulcerative Colitis
Crohn Disease
Medical Subject Headings
Incidence
Azathioprine
Tacrolimus
Proxy
Methotrexate
MEDLINE
Cyclosporine
Libraries
Language
Databases
Confidence Intervals

Keywords

  • 6-mercaptopurine
  • Azathioprine
  • Inflammatory bowel disease
  • Malignancy

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Meta-analysis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease. / Masunaga, Yukari; Ohno, Keiko; Ogawa, Ryuichi; Hashiguchi, Masayuki; Echizen, Hirotoshi; Ogata, Hiroyasu.

In: Annals of Pharmacotherapy, Vol. 41, No. 1, 01.2007, p. 21-28.

Research output: Contribution to journalArticle

Masunaga, Yukari ; Ohno, Keiko ; Ogawa, Ryuichi ; Hashiguchi, Masayuki ; Echizen, Hirotoshi ; Ogata, Hiroyasu. / Meta-analysis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease. In: Annals of Pharmacotherapy. 2007 ; Vol. 41, No. 1. pp. 21-28.
@article{2fbf0eed904b45989390863d0250d9c6,
title = "Meta-analysis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease",
abstract = "BACKGROUND: There is a concern as to whether long-term administration of immunosuppresants in patients with inflammatory bowel disease (IBD) would increase the risk of malignancy. OBJECTIVE: To compare the risks of developing malignancy between patients with IBD treated with immonosuppressive agents and patients with IBD not receiving these agents. METHODS: A systematic literature review was conducted, and a meta-analysis was performed on data retrieved from cohort studies that followed patients with IBD who received immunosuppressive agents for more than a year and documented the incidence of newly developed malignancy. An electronic search was conducted using MEDLINE (1966-September 2006), the Cochrane Library (issue 3, 2006), and Japana Centra Revou Medicina (1981-September 2006). Medical subject headings used in the searches were azathioprine, 6-mercaptorine, cyclosporine, methotrexate, tacrolimus, inflammatory bowel disease, and neoplasms. We imposed no language limitation in the searches. Additionally, a manual search of reference listings from all articles retrieved from the electronic databases was performed. Using data obtained from control groups or population-based studies, the incidence of newly developed malignancy in patients with IBD treated with immunosuppressive agents was compared with that of patients with IBD who were not receiving immunosuppressive agents. Statistical analysis for the change in risk of receiving immunosuppressive agents. Statistical analysis for the difference (WMD) normalized to per person-year and its 95{\%} confidence interval. RESULTS: Nine cohort studies met the inclusion criteria for this meta-analysis. Analysis of these studies showed no discernible difference (WMD -0.3 × 10 -3/ person-year; 95{\%} CI -1.2 × 10-3) in the incidence of any kind of malignancy in patients with IBD who received immunosuppressants compared with those who did not receive immunosuppresants. No significant difference in WMD was observed when the data from patients with either Crohn's disease (CD) or ulcerative colitis (UC) were analyzed separately. CONCLUSIONS: Our findings suggest that the administration of immunosuppressive agents in patients with either CD or UC probably does not confer a significantly increased risk of malignancy compared with patients with IBD who are not receiving these agents.",
keywords = "6-mercaptopurine, Azathioprine, Inflammatory bowel disease, Malignancy",
author = "Yukari Masunaga and Keiko Ohno and Ryuichi Ogawa and Masayuki Hashiguchi and Hirotoshi Echizen and Hiroyasu Ogata",
year = "2007",
month = "1",
doi = "10.1345/aph.1H219",
language = "English",
volume = "41",
pages = "21--28",
journal = "Annals of Pharmacotherapy",
issn = "1060-0280",
publisher = "Harvey Whitney Books Company",
number = "1",

}

TY - JOUR

T1 - Meta-analysis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease

AU - Masunaga, Yukari

AU - Ohno, Keiko

AU - Ogawa, Ryuichi

AU - Hashiguchi, Masayuki

AU - Echizen, Hirotoshi

AU - Ogata, Hiroyasu

PY - 2007/1

Y1 - 2007/1

N2 - BACKGROUND: There is a concern as to whether long-term administration of immunosuppresants in patients with inflammatory bowel disease (IBD) would increase the risk of malignancy. OBJECTIVE: To compare the risks of developing malignancy between patients with IBD treated with immonosuppressive agents and patients with IBD not receiving these agents. METHODS: A systematic literature review was conducted, and a meta-analysis was performed on data retrieved from cohort studies that followed patients with IBD who received immunosuppressive agents for more than a year and documented the incidence of newly developed malignancy. An electronic search was conducted using MEDLINE (1966-September 2006), the Cochrane Library (issue 3, 2006), and Japana Centra Revou Medicina (1981-September 2006). Medical subject headings used in the searches were azathioprine, 6-mercaptorine, cyclosporine, methotrexate, tacrolimus, inflammatory bowel disease, and neoplasms. We imposed no language limitation in the searches. Additionally, a manual search of reference listings from all articles retrieved from the electronic databases was performed. Using data obtained from control groups or population-based studies, the incidence of newly developed malignancy in patients with IBD treated with immunosuppressive agents was compared with that of patients with IBD who were not receiving immunosuppressive agents. Statistical analysis for the change in risk of receiving immunosuppressive agents. Statistical analysis for the difference (WMD) normalized to per person-year and its 95% confidence interval. RESULTS: Nine cohort studies met the inclusion criteria for this meta-analysis. Analysis of these studies showed no discernible difference (WMD -0.3 × 10 -3/ person-year; 95% CI -1.2 × 10-3) in the incidence of any kind of malignancy in patients with IBD who received immunosuppressants compared with those who did not receive immunosuppresants. No significant difference in WMD was observed when the data from patients with either Crohn's disease (CD) or ulcerative colitis (UC) were analyzed separately. CONCLUSIONS: Our findings suggest that the administration of immunosuppressive agents in patients with either CD or UC probably does not confer a significantly increased risk of malignancy compared with patients with IBD who are not receiving these agents.

AB - BACKGROUND: There is a concern as to whether long-term administration of immunosuppresants in patients with inflammatory bowel disease (IBD) would increase the risk of malignancy. OBJECTIVE: To compare the risks of developing malignancy between patients with IBD treated with immonosuppressive agents and patients with IBD not receiving these agents. METHODS: A systematic literature review was conducted, and a meta-analysis was performed on data retrieved from cohort studies that followed patients with IBD who received immunosuppressive agents for more than a year and documented the incidence of newly developed malignancy. An electronic search was conducted using MEDLINE (1966-September 2006), the Cochrane Library (issue 3, 2006), and Japana Centra Revou Medicina (1981-September 2006). Medical subject headings used in the searches were azathioprine, 6-mercaptorine, cyclosporine, methotrexate, tacrolimus, inflammatory bowel disease, and neoplasms. We imposed no language limitation in the searches. Additionally, a manual search of reference listings from all articles retrieved from the electronic databases was performed. Using data obtained from control groups or population-based studies, the incidence of newly developed malignancy in patients with IBD treated with immunosuppressive agents was compared with that of patients with IBD who were not receiving immunosuppressive agents. Statistical analysis for the change in risk of receiving immunosuppressive agents. Statistical analysis for the difference (WMD) normalized to per person-year and its 95% confidence interval. RESULTS: Nine cohort studies met the inclusion criteria for this meta-analysis. Analysis of these studies showed no discernible difference (WMD -0.3 × 10 -3/ person-year; 95% CI -1.2 × 10-3) in the incidence of any kind of malignancy in patients with IBD who received immunosuppressants compared with those who did not receive immunosuppresants. No significant difference in WMD was observed when the data from patients with either Crohn's disease (CD) or ulcerative colitis (UC) were analyzed separately. CONCLUSIONS: Our findings suggest that the administration of immunosuppressive agents in patients with either CD or UC probably does not confer a significantly increased risk of malignancy compared with patients with IBD who are not receiving these agents.

KW - 6-mercaptopurine

KW - Azathioprine

KW - Inflammatory bowel disease

KW - Malignancy

UR - http://www.scopus.com/inward/record.url?scp=33846448180&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846448180&partnerID=8YFLogxK

U2 - 10.1345/aph.1H219

DO - 10.1345/aph.1H219

M3 - Article

C2 - 17200426

AN - SCOPUS:33846448180

VL - 41

SP - 21

EP - 28

JO - Annals of Pharmacotherapy

JF - Annals of Pharmacotherapy

SN - 1060-0280

IS - 1

ER -